Despite current treatment regimens, heart failure remains the leading cause of morbidity and mortality in the developed world due to the limited capacity of adult mammalian ventricular cardiomyocytes to divide and replace ventricular myocardium lost from ischaemia-induced infarct 1,2 . Hence there is great interest to identify potential cellular sources and strategies to generate new ventricular myocardium 3 . Past studies have shown that fish and amphibians and early postnatal mammalian ventricular cardiomyocytes can proliferate to help regenerate injured ventricles 4-6 ; however, recent studies have suggested that additional endogenous cellular sources may contribute to this overall ventricular regeneration 3 . Here we have developed, in the zebrafish (Danio rerio), a combination of fluorescent reporter transgenes, genetic fate-mapping strategies and a ventricle-specific genetic ablation system to discover that differentiated atrial cardiomyocytes can transdifferentiate into ventricular cardiomyocytes to contribute to zebrafish cardiac ventricular regeneration. Using in vivo time-lapse and confocal imaging, we monitored the dynamic cellular events during atrial-to-ventricular cardiomyocyte transdifferentiation to define intermediate cardiac reprogramming stages. We observed that Notch signalling becomes activated in the atrial endocardium following ventricular ablation, and discovered that inhibiting Notch signalling blocked the atrial-to-ventricular transdifferentiation and cardiac regeneration. Overall, these studies not only provide evidence for the plasticity of cardiac lineages during myocardial injury, but more importantly reveal an abundant new potential cardiac resident cellular source for cardiac ventricular regeneration.
Despite current treatment regimens, heart failure remains the leading cause of morbidity and mortality in the developed world due to the limited capacity of adult mammalian ventricular cardiomyocytes to divide and replace ventricular myocardium lost from ischaemia-induced infarct 1,2 . Hence there is great interest to identify potential cellular sources and strategies to generate new ventricular myocardium 3 . Past studies have shown that fish and amphibians and early postnatal mammalian ventricular cardiomyocytes can proliferate to help regenerate injured ventricles [4] [5] [6] ; however, recent studies have suggested that additional endogenous cellular sources may contribute to this overall ventricular regeneration 3 . Here we have developed, in the zebrafish (Danio rerio), a combination of fluorescent reporter transgenes, genetic fate-mapping strategies and a ventricle-specific genetic ablation system to discover that differentiated atrial cardiomyocytes can transdifferentiate into ventricular cardiomyocytes to contribute to zebrafish cardiac ventricular regeneration. Using in vivo time-lapse and confocal imaging, we monitored the dynamic cellular events during atrial-to-ventricular cardiomyocyte transdifferentiation to define intermediate cardiac reprogramming stages. We observed that Notch signalling becomes activated in the atrial endocardium following ventricular ablation, and discovered that inhibiting Notch signalling blocked the atrial-to-ventricular transdifferentiation and cardiac regeneration. Overall, these studies not only provide evidence for the plasticity of cardiac lineages during myocardial injury, but more importantly reveal an abundant new potential cardiac resident cellular source for cardiac ventricular regeneration.
Atrial cardiomyocytes appear to have the remarkable capacity to divide in many adult vertebrate hearts including mammals during cardiac ventricular injury 7, 8 ; however, the role of these proliferating atrial cardiomyocytes remains unclear. To address this issue, we have generated in the zebrafish, a genetic cardiac ventricle-specific nitroreductase (NTR)-mediated ablation system 9 , Tg(vmhc:mCherry-NTR) s957 , using the ventricular myosin heavy chain (vmhc) promoter 10 . Thus, this ablation system permits the targeted destruction of ventricular cardiomyocytes after metronidazole (MTZ) treatment (Fig. 1 ). To track both atrial and ventricular cardiomyocytes during ventricular injury, we fused the mCherry fluorescent protein to NTR to label ventricular cardiomyocytes in red (venCherry), as well as using the atrial myosin heavy chain (amhc) promoter to create the Tg(amhc:eGFP) s958 transgenic line, which marks with enhanced green fluorescent protein the atrial cardiomyocytes (atrGFP). As a result, we observed that the expression of mCherry and GFP in these reporter lines were restricted to ventricular and atrial cardiomyocytes, respectively, throughout development (Supplementary Fig. 1a-d) . In order to visually monitor in vivo the dynamic cellular events that transpire throughout ventricular injury and regeneration within the same animal, the ventricles of Tg(vmhc:mCherry-NTR); Tg(amhc:eGFP) hearts were ablated at 3-4 days post-fertilization (dpf), an age when the zebrafish heart has completed cardiac looping and cardiac chamber cardiomyocytes have fully differentiated 11 , but the zebrafish remains optically clear. As a result, 4 dpf ablated vmhc:mCherry-NTR ventricles displayed statistically significant reduction in venCherry fluorescence by 24 h post MTZ treatment (hours post treatment, hpt) ( Fig. 1b, Supplementary Fig. 2a ). This rapid decrease in venCherry fluorescence was accompanied by a reduction in ventricular size ( Fig. 1b , Supplementary Fig. 2b ) and function (fractional area change decreased from 42% to 16% at 24 hpt, n 5 5, P 5 0.004; Supplementary Videos 1 and 2; Supplementary Fig. 3a -c), leading to pericardial oedema and overall decreased blood circulation. TUNEL (TdT-mediated dUTP nick end labelling) cell-death assays revealed that this decrease in ventricular function and size was due to an increase in ventricular cardiomyocyte death ( Fig. 1f ). Conversely, we observed that the atria significantly enlarged ( Supplementary Fig. 2b ) and maintained normal contractile function ( Supplementary Fig. 3d ) during this reduction in ventricular size and function.
By 48 hpt, we observed in these injured ventricles an accretion of new venCherry 1 cardiomyocytes adjacent to the atrioventricular canal (AVC) ( Fig. 1c , asterisk), which continued to expand across the ventricle over the next 48 h to restore lost ventricular myocardium nearest the AVC by 96 hpt (Fig. 1d , asterisk). Subsequently, ventricular cardiac function recovered in these injured hearts to nearly that of age-matched controls by 96 hpt (fractional area change of ablated and control ventricle was 38% and 39%, respectively; n 5 5, P 5 0.49; Supplementary Fig.  3c ), allowing for survival of these ventricle-ablated fish into adulthood. Anti-phospho-histone H3 immunostaining revealed that ventricular injury resulted in not only ventricular but also atrial cardiomyocyte proliferation ( Fig. 1g, h ; Supplementary Fig. 4 ), as observed in other cardiac injury and regeneration models 4, 6, 12 . Although this cardiomyocyte cell division peaked by 48 hpt in both cardiac chambers (Supplementary Fig. 4d, e ), there was a particularly significant atrial cardiomyocyte proliferative increase that remained elevated up to 84 hpt.
During the ventricular recovery, we observed the presence of low expressing atrGFP cardiomyocytes (atrGFP lo ) within the injured ventricle near the AVC between 24-48 hpt (Fig. 1b , c and 2b), whereas atrGFP cardiomyocytes were never observed in the ventricle of control hearts ( Fig. 2a ). Optical sections of the AVC region revealed that these atrGFP lo cardiomyocytes co-expressed the venCherry marker in the ablated ventricles ( Fig. 2b , right panel, arrowheads), but were not detected in unablated ventricles ( Fig. 2a , right panel). To further confirm these findings, we examined the gene expression of amhc and vmhc in the hearts of these ablated ventricles and observed that amhc was expressed throughout the atrium and frequently in the ventricle at the AVC by 24-48 hpt, where we observed the double-labelled atrGFP lo venCherry 1 cardiomyocytes; whereas vmhc was expressed throughout the ventricle, but rarely in the atrium and only at 12-24 hpt. ( Supplementary Fig. 5 ). Thus, these findings indicate that during injury, pre-existing atrial cardiomyocytes may migrate to the ventricle to transdifferentiate into ventricular cardiomyocytes, or alternatively, proliferating dedifferentiated ventricular cardiomyocytes may need to activate an atrial program before fully differentiating into ventricular cardiomyocytes. Given that we still observe some proliferating pre-existing venCherry cardiomyocytes that never express the atrGFP marker, we speculate that the atrial-to-ventricular cardiomyocyte transdifferentiation model may be more plausible.
To further investigate this transdifferentiation model, we performed genetic lineage tracing of atrial cardiomyocytes in the Tg(vmhc:mCherry-NTR) ventricle ablation model using an atrial cardiomyocyte specific tamoxifen-inducible Cre transgenic line, Tg(amhc:CreERT2) sd20 , and the indicator transgenic line, Tg(b-actin2:loxP-DsRed-STOP-loxP-eGFP) s928 , hereafter referred to as b-actin2:RSG (b-actin2 is also known as actb2), which can effectively label most cells, including cardiomyocytes and endocardial cells, with GFP after tissue-specific Cre-mediated excision of the floxed dsRed cassette 5, 13 . Treating the Tg(vmhc:mCherry-NTR; amhc: CreERT2; b-actin2:RSG) fish with 4-hydroxytamoxifen (4-HT) at 3 dpf for 4-6 h, effectively GFP labelled all atrial cardiomyocytes by Cre recombination (cre-atrGFP 1 ) without ectopic GFP-labelling of ventricular cardiomyocytes by 5 dpf (Fig. 2c , e; Supplementary Fig. 6a -c); whereas vehicle control treatment resulted in no Cre-mediated GFP labelling of any cells ( Supplementary Fig. 6d ). We subsequently MTZ-ablated the ventricles of these cre-atrGFP-labelled hearts at 5 dpf ( Fig. 2e ). In the ablated group, these cre-atrGFP 1 cardiomyocytes at 96 hpt and at 12 months were present in not only the atrium but also in the ventricle where many of them also co-expressed venCherry (n 5 73/76; Fig. 2f , Supplementary Figs 7i, j and 8b, c). However, in the control nonablated group at 96 hpt and at 12 months, cre-atrGFP 1 cardiomyocytes were only observed in the atrium but never in the ventricle (n 5 0/54; Fig. 2d ; Supplementary Figs 6c and 8a) . Using time-lapse imaging within the same ventricle-ablated Tg(vmhc:mCherry-NTR; amhc:CreERT2; b-actin2:RSG) hearts, we observed the gradual and contiguous extension of these cre-atrGFP 1 cardiomyocytes at the AVC into the ventricle where they began to restore ventricular contractile function nearest the AVC and also to exhibit venCherry expression, indicating that they were transdifferentiating from atrial to ventricular cardiomyocytes ( Fig. 2g -j, Supplementary Videos 3-5). Electrophysiologic intracellular recordings revealed that these cre-atrGFP 1 venCherry 1 cardiomyocytes within the regenerating ventricle exhibited electrical attributes similar to endogenous cre-atrGFP 2 venCherry 1 ventricular cardiomyocytes and distinct from atrial cardiomyocytes (that is, cre-atrGFP 1 venCherry 2 ) ( Supplementary Fig. 9 ). Furthermore, in situ analysis showed that the ventricular specific markers irx1a and vmhc were expressed in ventricular cardiomyocytes at the AVC where cre-atrGFP 1 ventricular cardiomyocytes reside (Supplementary Fig. 10 ). Moreover, we also observed that the atrial chamber cre-atrGFP 1 fluorescence intensity and size in hearts with ablated ventricles appeared to be significantly greater than that of control hearts (compare Fig. 2f to 2d, Supplementary Fig. 7k, l) , an observation consistent with the increased atrial size, fluorescence intensity and cardiomyocyte proliferation observed after ventricular injury ( Supplementary Figs 2a, b and 4d ). Finally, in adult zebrafish ventricles ablated at 4 months, we discovered that the contribution of transdifferentiated atrial cardiomyocytes to the regenerating ventricle was diminished ( Supplementary Fig. 11 ), indicating that this cardiac transdifferentation process may be age-dependent.
To investigate whether these atrial-derived ventricular cardiomyocytes maintained the atrial program, we examined Amhc protein expression by S46 antibody immunostaining in the ventricle-ablated Tg(vmhc:mCherry-NTR; amhc:CreERT2; b-actin2:RSG) hearts, and observed that cre-atrGFP 1 atrial cardiomyocytes continued to express Amhc in the atrium (Fig. 2m, n) , but not in the ventricle. However, before their subsequent differentiation into ventricular cardiomyocytes amhc:CreERT2; b-actin2:RSG) ablated hearts at 96 hpt; venCherry 1 (red) (k); cre-atrGFP 1 (green) (l, p); anti-Amhc (S46) (magenta) (m, q); merge (n, r) and vmhc RNA (blue) (o). Asterisk indicates venCherry 1 cre-atrGFP 1 Amhc 2 (n) or vmhc 1 cre-atrGFP 1 Amhc 2 (r) ventricular cardiomyocytes. Arrowhead indicates venCherry 2 cre-atrGFP 1 Ahmc 2 (n) or vmhc 2 cre-atrGFP 1 Amhc 2 (r) ventricular cardiomyocytes. A, atrium; V, ventricle; dashed lines indicate the atrioventricular boundary.
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(cre-atrGFP 1 Amhc 2 venCherry 1 Fig. 2n, Supplementary Fig. 7d , asterisk), we discovered that cre-atrGFP 1 cardiomyocytes may first exist in an intermediate dedifferentiation stage (cre-atrGFP 1 Amhc 2 venCherry 2 , Fig. 2n , Supplementary Fig. 7d, arrowheads) , in which they no longer maintain the atrial program (Amhc 2 ) but have not yet activated the ventricular program (venCherry 2 ). Consistent with these findings, vmhc fluorescent in situ hybridization also revealed a population of cre-atrGFP 1 cardiomyocytes devoid of vmhc expression within the recovering ventricle ( Fig. 2r, Supplementary Fig. 7h, d arrowheads) . Because of this possible dedifferentiation of atrial cardiomyocytes, we also examined the expression of cardiac progenitor markers in the ventricle-ablated hearts. Although we did not detect Isl1 in the injured hearts (data not shown), we did observe the re-expression of gata4, hand2, nkx2.5, tbx5a and tbx20 ( Supplementary Fig. 12 ), as well as increased expression of Mef2 in the atrium, ventricle and outflow tract of the recovering ventricle-ablated hearts ( Supplementary Fig. 13 ). Furthermore, Mef2 immunofluorescence revealed not only that many of the intermediate dedifferentiated cre-atrGFP 1 cardiomyocytes within the recovering ventricle (that is, cre-atrGFP 1 venCherry 2 ) expressed Mef2 (Supplementary Fig. 13p, arrowheads) , but also that the new Mef2 1 cells at the outflow tract did not express myosin heavy chain (Supplementary Fig. 13e-h) , indicating that these cells may be cardiac progenitor cells, which have not yet differentiated into mature cardiomyocytes. Overall, these data indicate that atrial cardiomyocytes may acquire cardiac progenitor cell attributes to become ventricular cardiomyocytes and moreover that the zebrafish second heart field residing near the outflow tract 14, 15 may also contribute ventricular cardiomyocytes to recover the distal portion of the injured ventricle.
To further elucidate the cellular events that take place during ventricular injury and recovery including the atrial-to-ventricular cardiac lineage switch, we analysed the cardiomyocyte structural and morphologic changes after ventricular ablation. To study this, we crossed the Tg(vmhc:mCherry-NTR) fish to the reporter lines, Tg(cmlc2:actinin-eGFP) sd10 (cmlc2 is also known as myl7) or Tg(cmlc2:eGFP-ras) s883 , which labels sarcomeric structures 16 or outlines cardiomyocytes 17 , respectively ( Fig. 3a-j, Supplementary Fig. 14) , as well as performed N-cadherin immunostaining to examine cardiomyocyte cell-cell junctions ( Fig. 3k-o) . During ventricular injury, damaged ventricular cardiomyocytes lost their rod-like shape 18 , particularly at the outer curvature ( Fig. 3g, h, asterisks) , and as reported 4,5 , exhibited disorganized or complete loss of sarcomeres and cell junctions between 12-24 hpt (Fig. 3b, c, l, m, asterisks) , when ventricular function has reached its lowest point. In contrast, during ventricular recovery (36-48 hpt), we observed the reorganization of not only ventricular but also atrial cardiomyocyte sarcomeres, morphologies and adhesion junctions ( Fig. 3d, i, n, Supplementary Fig. 14e ). In particular, atrial cardiomyocytes at the AVC became more circular ( Supplementary Fig. 14b, e ) and lost N-cadherin localization at their cell junctions when they began to extend into the ventricle and differentiate into ventricular cardiomyocytes (Fig. 3n ). Moreover, we also observed that these migrating atrial cardiomyocytes at the AVC initially displayed disorganized sarcomeric structures ( Supplementary Fig. 14d, asterisk) , but after populating the ventricle, exhibited enriched actinin-eGFP at the cell periphery/cortex (Fig. 3d, Supplementary Fig. 14d arrow) and frequently short bundles of actinin-eGFP labelled z-line structures (Fig. 3d, Supplementary Fig. 14d, arrowhead) , closely resembling de novo sarcomere assembly 16 . By 96 hpt when the ventricle has functionally recovered, the ventricular cardiomyocytes derived from reprogrammed atrial cardiomyocytes exhibited not only organized sarcomeres that align with other ventricular cardiomyocytes, but also localization of N-cadherin at the cell junctions ( Fig. 3e, o) . Overall, these results reveal that atrial cardiomyocytes undergo activated cellular reprogramming following ventricular myocardial injury in order to initiate cellular events that permit their proliferation, migration and transdifferentiation to facilitate ventricular regeneration.
Because previous studies have shown that endocardial activation may be essential to regulate cardiac regeneration 19 , we examined Raldh2 (also known as Aldh1a2) expression in ventricle ablated Tg(vmhc:mCherry-NTR) fish. Although Raldh2 is expressed weakly in control treated hearts ( Supplementary Fig. 15a, c, g, h) , its expression is induced throughout the endocardium of the ventricle-ablated hearts by 24-48 hpt (Supplementary Fig. 15b, d, k, l) . Using the Tg(tp1:eGFP) um14 Notch reporter line 20 , we also observed that Notch signalling (that is, tp1:eGFP expression) was specifically activated in atrial endocardial cells of Tg(vmhc:mCherry-NTR) MTZ-ablated hearts, as detected by the overlapping expression between tp1:eGFP and kdrl:mCherry (Tg(kdrl: ras-mCherry) s896 ), which labels endothelial and endocardial cell membranes in red 21 (compare Fig. 4a to b, 4e to f). Whole mount in situ hybridization of Notch signalling components revealed that notch1b and deltaD, which are normally present in the AVC and outflow tract LETTER RESEARCH of uninjured hearts (Fig. 4i, m) , exhibited increased AVC expression as well as activated atrial expression in ventricular-ablated hearts (Fig. 4j, n) ; however, deltaC was absent ( Supplementary Fig. 16 ). Because tp1:eGFP expression was strong in the ventricle (Fig. 4a, b) , but notch1b and deltaD expression was not, we performed gfp RNA in situ analysis to confirm this tp1:eGFP ventricular fluorescence and discovered that RNA expression of gfp was weak to negligible in both uninjured and injured ventricles ( Supplementary Fig. 17a, b) , indicating that the relatively robust tp1:eGFP ventricular fluorescence may be due to eGFP protein perdurance. Finally, we investigated whether these Notch-activated atrial endocardial cells genetically marked by Tg(kdrl:Cre) s898 ; Tg(b-actin2:RSG) 13 could reprogram into cardiomyocytes to contribute to the regeneration of the ventricle-injured heart, but found no evidence for such an event (data not shown). Conversely, we did not observe any of the genetically marked atrial cardiomyocytes (cre-atrGFP 1 ) becoming endocardial cells (Supplementary Fig. 15i-l) . Thus, to further investigate the importance of this injury-induced atrial Notch activation, we treated ventricle-ablated hearts with the c-secretase inhibitor, DAPT. As a result, DAPT treatment decreased the ability of these hearts to restore their ventricular morphology and function after injury (control 81%, n 5 96/119 vs. DAPT-treated 39%, n 5 52/132; Fig. 4h ), which may be due to overall decreased atrial and ventricular cardiomyocyte proliferation ( Supplementary Fig. 18 ). To determine how DAPT impairs this recovery process, we examined the expression of tp1:eGFP as well as the migration of genetically labelled atrial cardiomyocytes in DAPT-treated ventricle-injured hearts. We observed not only decreased tp1:eGFP expression in the atrium (Fig. 4d ), but also a reduction in the migration of cre-atrGFP 1 atrial cardiomyocytes into the injured ventricle ( Fig. 4g ). Consistent with these findings, DAPT also inhibited notch1b, deltaD and tp1:egfp expression in the atrium of ventricle-injured hearts (Fig. 4l, p, Supplementary Fig. 17d ), but increased notch1b and deltaD in the outflow tract of uninjured hearts (Fig. 4k, o) . Thus, these data indicate that atrial endocardial Notch activation may be crucial to non-cell-autonomously regulate ventricle regeneration through the modulation of atrial-to-ventricular transdifferentiation.
Overall, these results reveal that in vivo reprogramming of differentiated atrial cardiomyocytes can be induced by cardiac ventricular injury through Notch-mediated signalling and proceeds in distinct intermediate stages ( Supplementary Fig. 19 ) in order to provide a novel endogenous cellular source for cardiac ventricular regeneration in zebrafish. Similar to recent cardiac-injury studies in zebrafish and mouse neonatal hearts, this process may be mediated through the activation of Raldh2 and Notch pathways 19, 22 , which may lead to sarcomeric reorganization 4, 5 , cardiomyocyte migration 4, 5 , and the re-expression of key early cardiac transcriptional regulators such as Gata4, Hand2, Mef2, Nkx2.5, Tbx5, and Tbx20 5, 6, 23 . Although Raldh2 was expressed throughout the endocardium of the ventricle-injured heart as previously described 6, 19 , Notch signalling was activated primarily in the atrial endocardium. As a result, we speculate that Notch-activated atrial endocardium may influence the atrial myocardium, just as Notch signalling in the ventricular endocardium influences ventricular trabeculation 24 . Given that previous studies have shown that specific congenital heart diseases can arise from aberrant Notch signalling 25 , our studies also raise the possibility that abnormal reprogramming of cardiac lineages may be partially responsible for these heart defects.
Although it remains to be elucidated whether mammalian atrial cardiomyocytes may also have a comparable transdifferentiation capacity, recent studies have indicated that mammalian cardiomyocyte progenitor cells (CPMCs) appear to be enriched in the atrium [26] [27] [28] suggesting that the zebrafish transdifferentiating atrial cardiomyocytes may be analogous to the atrial-resident adult CPMCs. Alternatively, mammalian atrial cardiomyocytes could reprogram into ventricular cardiomyocytes through the reactivation of early cardiac transcriptional factors, a process recently reported to reprogram cardiac fibroblasts into ventricular cardiomyocytes in mouse hearts 29, 30 . Thus, future studies in mammalian ventricular injury models 6 using similar atrial genetic lineage tracing strategies as presented here, are warranted to further investigate the potential of this cardiac reprogramming process as an endogenous cellular regenerative therapy in human heart failure patients. Such a cardiac regenerative strategy could overcome current obstacles facing the translation of stemcell therapies for heart failure patients, including the differentiation of autologous cardiac progenitor cells into ventricular cardiomyocytes as well as the delivery and integration of these differentiated ventricular cardiomyocytes into the patient's ventricular myocardium.
METHODS SUMMARY
Chamber-specific ablation and reporter lines were generated using the standard I-SceI meganuclease transgenesis technique (details in Methods). To perform ventricular cardiomyocyte ablation, Tg(vmhc:mCherry-NTR) zebrafish were treated with 5 mM MTZ as previously described 9 . For lineage tracing experiments, Tg(vmhc:mCherry-NTR; amhc:CreERT2; b-actin2:RSG) zebrafish were treated with 10 mM 4-hydroxytamoxifen as previously described 5 . For Notch inhibition studies, zebrafish were treated with 100 mM DAPT. Live imaging, heart contraction, immunofluorescence and whole mount in situ hybridization were performed as described in the Methods.
Full Methods and any associated references are available in the online version of the paper. 
RESEARCH LETTER

